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ABSTRACT
Background
Lung cancer is the leading cause of cancer-related death worldwide. Currently, tumor, node,
metastasis (TNM) staging provides the most accurate prognostic parameter for patients with
non-small cell lung cancer (NSCLC). However, the overall survival of patients with resectable
tumors varies significantly, indicating the need for additional prognostic factors to better
predict the outcome of the disease, particularly within a given TNM subset.
Methods and Findings
In this study, we investigated whether adenocarcinomas and squamous cell carcinomas
could be differentiated based on their global aberrant DNA methylation patterns. We
performed restriction landmark genomic scanning on 40 patient samples and identified 47
DNA methylation targets that together could distinguish the two lung cancer subgroups. The
protein expression of one of those targets, oligodendrocyte transcription factor 1 (OLIG1),
significantly correlated with survival in NSCLC patients, as shown by univariate and multivariate
analyses. Furthermore, the hazard ratio for patients negative for OLIG1 protein was significantly
higher than the one for those patients expressing the protein, even at low levels.
Conclusions
Multivariate analyses of our data confirmed that OLIG1 protein expression significantly
correlates with overall survival in NSCLC patients, with a relative risk of 0.84 (95% confidence
interval 0.77–0.91, p , 0.001) along with T and N stages, as indicated by a Cox proportional
hazard model. Taken together, our results suggests that OLIG1 protein expression could be
utilized as a novel prognostic factor, which could aid in deciding which NSCLC patients might
benefit from more aggressive therapy. This is potentially of great significance, as the addition of
postoperative adjuvant chemotherapy in T2N0 NSCLC patients is still controversial.
The Editors’ Summary of this article follows the references.
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Lung cancer is the leading cause of cancer-related death
worldwide [1]. It is estimated that over 1.2 million people are
diagnosed with lung cancer annually, and 1.1 million die from
the disease [2]. Despite intensive research over the past
decades, the ﬁve-year survival of lung cancer patients remains
poor [3]. Currently, the most accurate prognostic factor for
patients with non-small cell lung cancer (NSCLC) is tumor,
node, metastasis (TNM) clinico-pathologic staging [4]. Never-
theless, patients with early-stage lung cancer exhibit a wide
spectrum of survival, indicating the need for additional
prognostic parameters to better predict the outcome of the
disease [5]. Thus, much effort has been dedicated to
identifying molecular markers that might improve the
classiﬁcation of NSCLC. Such markers not only should give
prognostic information, but could help identify patients that
would beneﬁt from novel therapeutic strategies or, alter-
natively, those for which additional treatment is not needed.
A recent example of the utility of such markers is the
identiﬁcation of gene expression proﬁles that predict high
risk of recurrence of localized lung cancer [6].
Over the past decade it has become evident that the cancer
genome is marked by epigenetic modiﬁcations that contrib-
ute to the deregulation of transcription proﬁles [7,8]. Of
particular interest is the observation that certain genes
demonstrate differential susceptibility to epigenetic dereg-
ulation. That is, some genes are targeted for promoter
methylation in only some tumor types [9,10], while others are
common targets for DNA methylation in several types of
neoplasias [11]. Thus, a genome-wide scan for DNA methyl-
ation in NSCLC could uncover new clinically relevant
molecular targets.
We analyzed primary human lung tumor samples via
restriction landmark genomic scanning (RLGS) [12] to
identify DNA sequences differentially methylated between
the two major NSCLC subgroups, adenocarcinomas and
squamous cell carcinomas (SCCs). We uncovered promoter
methylation patterns characteristic for both NSCLC subtypes
and describe a novel marker, oligodendrocyte transcription factor 1
(OLIG1), whose expression correlates with overall survival in
NSCLC patients, as validated by univariate and multivariate
analyses.
Methods
Procurement of Primary Human Tissue Samples
Primary lung cancer and adjacent tumor-free tissue
samples were procured through the Cooperative Human
Tissue Network at The Ohio State University James Cancer
Hospital and The University of Michigan following approved
Internal Review Board protocols. Consent from participants
was waived under CFR 46 subpart A. A total of 70 snap-frozen
matched tumor-free/adenocarcinomas and 70 snap-frozen
matched tumor-free/SCCs were procured. For immunohisto-
chemical studies, two lung tissue microarrays (TMAs) were
generated. All specimens included in these arrays were cored
from formalin-ﬁxed parafﬁn-embedded tissue blocks. TMA1
comprised 67 adenocarcinomas, 82 SCCs, and six tumor-free
lung samples arrayed in quadruplicate. TMA2 comprised 74
adenocarcinomas and 79 SCCs arrayed in triplicate. DNA
isolated from peripheral blood mononuclear cells procured
from random cancer-free donors was utilized as a negative
control for DNA methylation. In an effort to facilitate the
tracking of which tumor specimens were utilized only once in
this study versus those employed in several experimental
approaches, each specimen has been assigned a unique
identiﬁer. Adenocarcinomas are denoted as Adeno followed
by a number, while squamous cell carcinomas are denoted as
SCC followed by a number.
RLGS
RLGS was performed as previously described [13]. To avoid
potentially confounding factors, such as age-related DNA
methylation [14], samples were selected so that gender, race,
and age range would be comparable between the adenocar-
cinoma and the SCC tumor subsets (Table S1). RLGS proﬁles
of primary tumors and tumor-free lung from the same
patient were superimposed and visually inspected for differ-
ences in the presence and/or intensity of radiolabeled
fragments. The investigator performing the analysis was
blinded as to the cancer subtype of each sample. The use of
control tissues derived from the same patient as the tumor
sample ensured that DNA polymorphisms that might be
present at any of the restriction enzymes’ recognition sites
would not introduce a bias in the analysis.
Identification of RLGS Fragments
RLGS fragments of interest that had not already been
identiﬁed in our laboratory were cloned with the aid of either
a human NotI–EcoRV or a human AscI–EcoRV plasmid
library, as previously described [13,15,16]. Alternatively, a
PCR-based approach was employed to identify RLGS frag-
ments not present in the libraries [16].
RNA Isolation and Quantitative Real-Time PCR
Total RNA from primary human samples and human lung
cancer cell lines was isolated and puriﬁed as previously
described [17]. RNA integrity was assessed with the Agilent
2100 Bioanalyzer using an RNA 6000 LabChip kit (Agilent
Technologies, http://www.agilent.com). Only samples that
showed high level of RNA integrity were used for reverse
transcription [18]. For each sample, 1 lg of total RNA was
reverse transcribed using oligo dT (Invitrogen, http://www.in-
vitrogen.com), as previously described [19]. Given the fact
that OLIG1 is an intronless gene, regular PCR was performed
on DNAseI-treated but not reverse-transcribed RNA samples
to ensure that no DNA contamination was present in the
RNA extracts. Quantitative OLIG1 expression was measured
using SYBR Green I (Bio-Rad, http://www.bio-rad.com) in an
iCycler (Bio-Rad). Calcium/calmodulin-dependent protein kinase
kinase 2 (CAMKK2) was used as internal control [19]. Primer
sequences and PCR conditions for all genes described in this
study are listed in Table S2.
Combined Bisulfite Restriction Analysis and Combined
Bisulfite Restriction Analysis Coupled with the Agilent
2100 Bioanalyzer Platform
Combined bisulﬁte restriction analysis (COBRA) was
performed on BAHD1 and DMRTA1 as previously described
[20]. Brieﬂy, 181-bp and a 218-bp fragments from the BAHD1
and DMRTA1 genes, respectively, were ampliﬁed by PCR
from bisulﬁte-treated DNAs. The PCR products were puriﬁed
and digested with 10 U of BstUI (New England Biolabs, http://
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electrophoresed in an 8% polyacrylamide gel and visualized
via ethidium bromide staining. Primers and PCR conditions
are listed in Table S2.
Combined bisulﬁte restriction analysis coupled with the
Agilent 2100 bioanalyzer platform (Bio-COBRA) was per-
formed as previously described [19,21] on 41 out of the 59
samples utilized to assess deletions at the OLIG1 locus. The
reduction in the number of samples analyzed by Bio-COBRA
was due to limitations in the amount of tumor DNA available
from some specimens. Brieﬂy, genomic DNA was isolated
from human primary lung tumors, which was then mechan-
ically sheared and bisulﬁte treated [22]. Bisulﬁte-treated
DNAs were PCR ampliﬁed with OLIG1-speciﬁc primers (Table
S2), puriﬁed, and digested with 10 U of BstUI (New England
Biolabs) at 60 8C for 4 h. We electrophoresed 5 ll of the
digestion reaction in an 8% polyacrylamide gel and visualized
the digestion patterns via ethidium bromide staining. We
loaded 1 ll of each digestion product onto a DNA 500
LabChip and assayed them using the Agilent 2100 Bioana-
lyzer. Chromatograms were visually examined, and the raw
data generated from the assay was plotted to obtain the
ﬂuorescence values for each of the digestion fragments. The
methylation percentage for each sample was calculated as
follows: ﬂuorescence of methylated products/(ﬂuorescence of
methylated products þ ﬂuorescence of unmethylated prod-
uct).
OLIG1 Luciferase Assay
Using primers tagged with NotIo rEcoRV sequence tails,
four OLIG1 constructs were generated by PCR (Table S2). The
constructs were directionally cloned into a pGL3-Basic vector
(Promega, http://www.promega.com) modiﬁed to contain NotI
and EcoRV restriction sequences in its multiple cloning site.
A549 cells were plated at a density of 2310
4 cells/35-mm well
in RPMI-1640 medium (Cellgro, http://www.cellgro.com)
supplemented with heat-inactivated 10% FBS (Cellgro) the
day before transfection. The next day, cells were transfected
as previously described [17]. A promoterless pGL3-Basic
vector was used as the negative control for expression and a
pGL3-Basic vector containing the E2F3a promoter was used
as the positive control. Renilla luciferase was used as the
transfection efﬁciency-normalizing factor. Luciferase activity
was measured using the Dual Luciferase assay system
(Promega). All measurements were performed in triplicate
and the experiment was repeated three times.
5-aza-29Deoxy-Cytidine Treatment of Human Lung Cancer
Cell Lines
Human NSCLC cell lines A549 and H1299 were cultured
for two days and then treated with 1 lM of 5-aza-dC (Sigma-
Aldrich, http://www.sigmaaldrich.com) for 48 and 72 h as
previously described [17]. After treatment, total RNA was
isolated as previously described [17].
Assessment of OLIG1 Deletions in Primary Tumors
DNA was isolated from snap-frozen tissues as previously
described [13]. The DNAs were sheared and diluted to a ﬁnal
concentration of 20 ng/ll. Real-time PCRs were performed
using SYBR Green I (Bio-Rad) in an iCycler (Bio-Rad).
CAMKK2 was used as internal control. All reactions were
performed in triplicate. The OLIG1 threshold crossing (Ct)
value for each sample was normalized to that of its internal
control by subtracting the OLIG1 Ct from the CAMKK2 Ct.
The OLIG1 level in the tumor samples was calculated by the
DCt method, setting the normalized OLIG1 values obtained
from the matching tumor-free DNA to 1. A sample was
considered to harbor a deletion at the OLIG1 locus if
reduction of OLIG1 at the DNA level was assessed to be
.25% compared to its matching normal control [23]. The
overall comparison for the frequency of deletions between
the adenocarcinomas and the SCCs was assess by a one-tail Z-
ratio and considered signiﬁcant if the result of the test was p
  0.050.
Bisulfite DNA Sequencing
Bisulﬁte DNA sequencing was performed on two adeno-
carcinomas, two SCCs, and the four tumor-free lung tissues
from the same patients, as previously described [17]. We
sequenced eight to ten individual clones per sample. Primer
sequences and PCR conditions are listed in Table S2.
Immunohistochemical Staining and Scoring of Primary
Lung Tumor Tissue Arrays and a Lung Cancer Cell Line
Array
Immunohistochemical staining of human primary lung
tumor samples was performed on TMA1 composed of
formalin-ﬁxed, parafﬁn-embedded specimens. Each specimen
was present four times in the array [24]. The array contained
67 different adenocarcinomas, 82 different SCCs, and six
tumor-free lung samples. Brain tissue cores were included as
positive controls for OLIG1 staining (Table S3 lists the clinical
features of the specimens included in this array). Validation
of the immunohistochemistry results generated from TMA1
was performed on an independent sample set (TMA2). This
sample set comprised 74 formalin-ﬁxed, parafﬁn-embedded
adenocarcinomas and 79 formalin-ﬁxed, parafﬁn-embedded
SCCs arrayed in triplicate (Table S4 lists the clinical features
of the specimens included in this array). A mouse monoclonal
anti-OLIG1 antibody (R&D Systems, http://www.rndsystems.
com) was used at 1:1,000 dilution for immunohistochemical
detection. Antibody binding was detected by incubating the
slides with a secondary polyclonal anti-mouse IgG antibody
(Amersham Biosciences, http://www.amersham.com). Positive
staining was visualized by incubating the slides with diami-
nobenzadine (Sigma-Aldrich).
The slides were examined by an experienced lung
pathologist (CM) and reviewed by the primary investigator
(RMB). The evaluation of the immunohistochemical results
was performed as follows: each tissue core was assigned an
‘‘OLIG1 index score,’’ calculated on two parameters, percent
of positive (stained) cells in the tumor epithelium and
intensity of staining [25]. Each parameter was subdivided into
three categories: for percent of positive cells, 0%–10% was
assigned a value of 1; 10%–50% was assigned a value of 2,
and .50% was assigned a value of 3. For the intensity of
staining, no staining was assigned a value of 1, weaker than
normal lung staining was assigned a value of 2, and staining
as strong as normal lung was assigned a value of 3 [26]. The
OLIG1 index for each core was then calculated by multi-
plying the value assigned to each parameter. In order to
ensure the accurate assessment of OLIG1 protein expression
in each tumor, either three or four cores of the same sample
were placed in the tissue arrays. This design helped overcome
PLoS Medicine | www.plosmedicine.org March 2007 | Volume 4 | Issue 3 | e108 0574
OLIG1 in Human Lung Cancerthe problem of tumor heterogeneity, which could affect the
results depending on what area of tumor is cored. The ﬁnal
OLIG1 index score for each sample was determined by
taking the average of the indexes given to each individual
core.
OLIG1 protein levels were also assessed via immunohis-
tochemistry in H1299 cells treated with 1 lM of 5-aza-dC for
48 and 72 h. After treatment, the cells were collected,
embedded in agar pellets, and ﬁxed in formalin as previously
described [17]. After ﬁxation, each pellet was cored twice and
placed on a single slide to create a cell line array. OLIG1
protein detection was performed following the same protocol
utilized on the human primary tissue arrays as previously
described.
Statistical Analysis
In order to identify candidate RLGS loci that show
frequent methylation in one tumor subtype compared to
the other, proportions of methylation in the two groups were
compared. The Fisher’s exact test was applied to compare
proportions, which avoids any violations of normal assump-
tions due to smaller sample sizes. Less conservative mid-p-
values were estimated, and 47 RLGS loci with p , 0.06 were
used for further analysis.
As methylation events are represented by binary variables,
hierarchical cluster analysis of patient samples was per-
formed by applying Jaccard noninvariant coefﬁcient similar-
ity metric [27], using the 47 RLGS loci with p , 0.06. Cluster
analysis was performed three times, once with the initial
group of 25 patients that was used to identify differential
DNA methylation between adenocarcinomas and SCCs, then
with a set of 15 new patients to validate the ﬁrst result, and
ﬁnally with both sample sets combined.
Real-time PCR data were analyzed by applying one-way
ANOVA analysis followed by Scheffe test for multiple
comparisons. Comparisons with p , 0.025 (97.5% CI) were
considered signiﬁcant.
Kruskal-Wallis rank sum tests and Fisher’s exact tests were
used to compare differences in baseline characteristics.
Univariate and multivariate regression analyses were per-
formed using the Cox proportional hazard regression model
to determine the effects of various prognostic variables. Age
was used as a dichotomous variable based on the median age
value of the patients in the sample sets. OLIG1 index was used
as a continuous variable composed of nine discrete values (1–
9). In the multivariate model, the assumption of proportional
hazards was examined for each variable by testing the
signiﬁcance of correlation coefﬁcient between transformed
survival time and the Schoenfeld residuals of that variable. All
statistical analyses were performed using Splus and R (version
2.0.1) (http://www.r-project.org) softwares.
Results
Genome-Wide DNA Methylation Analysis of Human
Adenocarcinomas and SCCs of the Lung
RLGS was performed on 11 adenocarcinomas (Adenos 1–
11) and 14 SCCs (SCCs 1–14) to determine if these two lung
tumor subtypes could be differentiated based on their
aberrant DNA methylation patterns. The samples were
selected so that gender, race, age range, and tumor differ-
entiation were comparablei nb o t hg r o u p s .R L G Sw a s
performed using both NotI and AscI as restriction landmark
enzymes. As previously reported [10], the recognition
sequences of these enzymes occur preferentially within CpG
islands as deﬁned by Gardiner-Garden and Frommer [28],
effectively creating a bias towards the assessment of DNA
methylation in promoter sequences [15]. Additionally, recent
bioinformatics analyses indicate that 92.7% of NotI sites fall
within the 59 end, inside, or 39 end of transcripts (R.V.
Davuluri, personal communication). The DNA methylation
proﬁle from each tumor was scored against a proﬁle
generated from tumor-free lung from the same patient. On
average, the methylation status of 3,442 RLGS loci (range:
2,590–4,108) was analyzed per sample. The variation in the
number of RLGS fragments analyzed per sample stemmed
from individual differences in the quality of RLGS gels. Low
level DNA degradation in speciﬁc samples resulted in RLGS
fragments located in the periphery of the gel to become
diffuse or not separated well enough to be analyzed
accurately in all specimens. Aberrant DNA methylation was
detected at least once in 395 of the total 4,108 different RLGS
loci scored. The average frequency of CpG island methylation
in the adenocarcinomas was 4.82% (range: 3.39%–6.26%) and
4.23% (range: 3.13%–5.42%) in the SCCs. The methylation
level for each sample was calculated based on the exact
number of RLGS loci scored for that sample.
We identiﬁed 36 RLGS loci, whose methylation frequency
was signiﬁcantly different (p   0.050, Fisher’s exact test)
between the adenocarcinomas and the SCCs in the study. Of
these, eight (22%) were methylated in only one of the tumor
subtypes and not the other. The remaining sequences were
methylated in both subtypes, but in varying frequencies
(Figure 1A).
Next, hierarchical clustering was performed to determine if
the aberrant methylation events detected in our RLGS scan
were sufﬁcient to distinguish the adenocarcinomas from the
SCCs (Figure 1B). The best segregation of the tumors
according to their subtype with the lowest number of
misclassiﬁcations was achieved when the DNA methylation
status of 47 RLGS loci was considered. While the adenocarci-
nomas clustered into one major group, the SCCs were split
into two groups, one of them branching closer to the
adenocarcinomas (SCCs 2, 10, and 14). Also, SCC8 and
SCC12 clustered within the adenocarcinoma group. In order
to validate if the DNA methylation status of these 47 RLGS
loci could be applied to distinguish a new set of adenocarci-
nomas from a new set of SCCs, RLGS was performed on 15
additional samples (Adenos 12–19 and SCCs 15–21). These
samples were also selected to ensure that gender, race, age
range, and tumor differentiation were comparable in both
tumor subtypes. Hierarchical clustering of these 15 samples
showed a pattern where, again, the adenocarcinomas sepa-
rated in one major group, while the SCCs were split into two
groups (Figure 1C); a segregation pattern also seen in the
combined cluster (Figure 1D). Interestingly, most of the SCCs
grouping close to the adenocarcinomas (SCC group 1) were
moderately differentiated (four of six), while the SCCs
clustering entirely separately from the adenocarcinomas
(SCC group 2) were predominantly poorly differentiated
(eight of 13). This distribution, though not statistically
signiﬁcant, could indicate a trend that the two aberrant
DNA methylation patterns observed in SCCs may reﬂect, in
part, the differentiation state of the tumor.
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Altogether, 33 of the 47 RLGS loci derived from our
analysis were cloned either previously or in this study [13,16].
Of those 33 sequences, 28 were associated with a CpG island,
and 26 matched an annotated gene locus (Table 1). Notably,
many of the identiﬁed loci resided in chromosomal bands
where loss of heterozygosity (LOH) had previously been
described in lung cancer and/or other neoplasias [29]. To
prioritize the experimental evaluation of the identiﬁed genes,
SYBR green real-time PCR was performed on a new set of 12
adenocarcinomas (Adenos 20–31) and 12 SCCs (SCCs 22–33).
The assay was carried out on 13 genes, those with the highest
degree of differential DNA methylation between the two
tumor subtypes. The real-time PCR results highlighted that of
these 13 genes, BAHD1, DMRTA1, and OLIG1 had the highest
differential mRNA levels between adenocarcinomas and
SCCs (p , 0.025, analysis of variance followed by Scheffe)
(Figure 2A).
Next, the human lung cancer cell lines A549 and H1299, in
which OLIG1, BAHD1, and DMRTA1 are methylated and not
expressed, were treated with 1 lM of 5-aza-29-deoxy-cytidine
(5-aza-dC) for 48 and 72 h. The mRNA levels of all genes were
up-regulated in at least one of the cell lines by 5-aza-dC
(Figure 2B). OLIG1 bisulﬁte DNA sequencing for both wild-
type cell lines is shown in Figure S1. To conﬁrm these results,
OLIG1 immunohistochemistry was performed on the H1299
cells. As expected, OLIG1 protein expression was up-
regulated upon treatment with the DNA demethylating agent
(Figure 2C). Due to the lack of commercial antibodies for
BAHD1 and DMRTA1, COBRA was performed on both genes
(Adenos 20–29 and SCCs 23–33). Our results showed that
partial DNA methylation for BAHD1 was detected in 90% of
the samples, while partial DNA methylation for DMRTA1 was
observed in 52% of them (unpublished data). These observa-
tions indicate that expression of BAHD1, DMRTA1, and
OLIG1 is directly or indirectly regulated by DNA methylation.
OLIG1 in Human Lung Cancer
Our DNA methylation, mRNA expression and 5-aza-dC
reactivation data, coupled with literature describing recur-
rent LOH at chromosome 21q22.1 in SCCs of the lung [30,31],
led us to select OLIG1 for further study. Frequent LOH at
microsatellite marker D21S12070 (43.8%) located 2.74 Mb
upstream and marker D21S1445 (39.3%) located 0.93 Mb
downstream of OLIG1 was described in two reports [30,31].
Given the large distance between the two microsatellite
markers, we tested the frequency of OLIG1 deletions by
directly assessing the presence of the OLIG1 gene sequence in
a subset of primary tumors. The assay was performed via
quantitative real-time PCR on 25 adenocarcinomas (Adenos
20–44) and 34 SCCs (SCCs 22–55). We found that that 36% (n
¼ 9) of the adenocarcinomas and 59% (n ¼ 20) of the SCCs
showed loss of OLIG1 DNA compared to tumor-free lung, and
the frequency of deletion was signiﬁcantly higher in SCCs (p¼
Figure 1. Aberrant DNA Methylation Profile and Cluster Analysis of Adenocarcinomas and SCCs of the Lung
(A) DNA methylation patterns of the 47 RLGS fragments that distinguish adenocarcinomas from SCCs as recorded for the 25 primary tumor samples
used to generate the cluster shown in (B). The adenocarcinoma and SCC sets are separated by a green line. Black boxes indicate DNA methylation; white
boxes indicate absence of DNA methylation; red boxes indicate that the DNA methylation status of that RLGS fragment could not be determined. Each
column represents a sample; each row represents an RLGS fragment.
(B–C) Hierarchical clustering of adenocarcinoma and SCC samples. (B) Cluster comprising 25 samples (11 adenocarcinomas, 14 SCCs), based on 47 DNA
methylation events. (C) Cluster comprising 15 samples (eight adenocarcinomas and seven SCCs), based on the DNA methylation information of the
same 47 sequences as cluster (B).
(D) Combined cluster from samples shown in clusters (B) and (C). SCCs groups 1 and 2 are underlined.
doi:10.1371/journal.pmed.0040108.g001
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OLIG1 in Human Lung Cancer0.042, one-tail Z-test) (Figure 2D). This result is in agreement
with previously published studies reporting signiﬁcantly
higher rates of LOH in SCCs than in adenocarcinomas
[30,31]. The DNA methylation data generated by RLGS
showed the same trend, with the frequency of OLIG1 DNA
methylation being signiﬁcantly higher in SCCs.
To determine the location of the OLIG1 promoter, we
generated four luciferase constructs (Figure 3A). The con-
structs were transfected individually into A549 cells and
assayed for luciferase activity. Our results showed that the
region 267 bp upstream of the OLIG1 transcription start site
was sufﬁcient to drive luciferase expression, and that a
putative enhancer element might be located between 267 bp
and  566 bp, because of the signiﬁcantly higher luciferase
activity of the longer construct (p , 0.001, analysis of
variance) (Figure 3A). Thus, we focused on the 560-bp region
upstream of OLIG1 for further DNA methylation analysis.
Bisulﬁte DNA sequencing was performed on eight human
lung samples (two adenocarcinomas, two SCCs, and their
matching tumor-free lung tissues). A 260-bp PCR product
spanning from  391 bp to  131 bp containing 25 CpG
dinucleotides was generated. Another 203-bp PCR product
containing 18 CpG dinucleotides was produced to cover the
region from þ296bp to þ499 bp, where the AscI site
(landmark enzyme in RLGS) is located. In both regions
tested, the levels of DNA methylation were signiﬁcantly
higher in SCCs than in adenocarcinomas (p , 0.001, one-tail
Z-test) (Figure 3B).
In order to establish a correlation between OLIG1 DNA
methylation, frequency of deletions at the OLIG1 locus and
OLIG1 mRNA expression, Bio-COBRA, a technique that
allows for the rapid and accurate quantiﬁcation of DNA
methylation in a sensitive and reproducible manner [19,21],
was performed on a subset (41 out of 59) of the samples
utilized to generate the OLIG1 deletion data already
described. The DNA methylation status of four BstUI sites
was measured in a 260-bp PCR product extending from
 391bp to  131bp of the OLIG1 locus. DNA methylation was
detected in 26 samples, ranging from 7.0% to 100% (mean
54.9%). These DNA methylation values were then combined
with mRNA expression and deletion data. In 11 out of 13
samples in which DNA methylation alone was detected,
reduced mRNA expression levels were shown compared to
normal lung, as also was shown in seven out of nine samples
in which OLIG1 deletions alone were detected. All 13 samples
in which concomitant OLIG1 DNA methylation and OLIG1
Table 1. Chromosomal Location and Associated Genes for the 33 out of 47 Cloned RLGS Loci
RLGS Locus Chromosomal Location Gene CGI Present CGI Location
a Reported LOH
b
n2E33 1p13.3 ALX3 Yes 59 Yes [49]
n4E07 1q23.3 Not annotated
c Yes 59 No
a3F21 1q42.11 TP53BP2 Yes 59 No
n4D22 2p13.2 EMX1 Yes 59 No
n2E68 2p13.2 P450RAI-2 Yes 59 No
n4D38 2p21 EPAS1 Yes 59 Yes [49]
n3B55 2q24.2 TBR1 Yes 39 Yes [50]
d
n4D30 3p21.31 MAPKAPK3 Yes 59 Yes [49]
n4B44 3q21.3 CHST13 Yes 59 Yes [49]
n4G92 4q24 NFKB1 Yes 59 Yes [51]
d
a3E30 4q34.1 AK125257 Yes 59 Yes [52]
n2D10 5p15.33 Not annotated
c Yes No
n3C74 5q14.1 SSBP2 Yes 59 Yes [30]
d
n4G43 9p21.3 DMRTA1 Yes 59 Yes [49]
n2D37 10q11.21 ALOX5 Yes 59 Yes [53]
d
n3F60 10q26.13 BUB3 Yes 59 No
a2C13 11q25 ACAD8 Yes 59 Yes [51]
d
n4F58 12q21.1 KCNC2 Yes 59 Yes [49]
n3G94 13q31.1 SPRY2 Yes 59 Yes [54]
d
n4E44 15q15.1 BAHD1 Yes 59 Yes [55]
d
n5E08 15q22.2 Not annotated
c Yes No
n2C39 16p13.12 Not annotated
c Yes No
n3D48 17q11.2 RNF135 Yes 59 Yes [56]
d
n5E41 18q21.1 Not annotated
c Yes Yes [49]
n3B47 18q23 SALL3 Yes 59 Yes [49]
n2D43 19q12 KIAA1474 No Yes [49]
n1D08 19q13.2 Not annotated
c Yes Yes [54]
d
n3E59 19q13.33 SLC17A7 No Yes [49]
n1F14 20q13.12 C20orf35 Yes 59 No
n3D66 20q13.33 TCEA2 No No
n2B59 20q13.33 BC052269 No No
a4D15 21q22.11 OLIG1 Yes 59 þ body Yes [30,31]
n4G68 22q13.32 Not annotated
c Yes Yes [54]
d
The loci were used to generate the clusters in Figure 1.
aCGI (CpG island) location: location of the CpG island with respect to the transcription start site of its associated gene.
bThe reported LOH column indicates whether the chromosomal band identified in our study has been previously associated with LOH in lung cancer.
cNot annotated: No annotated gene is reported for the specified locus.
dReports of LOH on tumors derived from organs other than lung.
doi:10.1371/journal.pmed.0040108.t001
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OLIG1 in Human Lung Cancerdeletions were detected showed reduced mRNA levels, while
two out of six of the samples in which no DNA methylation
or deletions were assessed showed a reduction in OLIG1
mRNA expression (Figure 4). Taken together, these data
indicate that DNA methylation and deletions at the OLIG1
locus in primary human lung tumors can be correlated with a
reduction in OLIG1 at the mRNA level.
OLIG1 Immunohistochemistry on Lung Tissue Arrays
OLIG1 immunohistochemistry was performed on TMA1
comprising 59 adenocarcinomas (Adenos 45–103), 74 SCCs
(SCCs 56–129), six tumor-free lung, and four human brain
specimens. The immunohistochemical results were scored
and an OLIG1 index value was assigned to each sample. The
index values ranged from one (no expression) to nine (normal
Figure 2. Real-Time PCR Analysis of Three Differentially Methylated Genes in Adenocarcinomas, SCCs, and Lung Cancer Cell Lines
OLIG1 immunohistochemistry in H1299 cells and OLIG1 deletion analysis.
(A) Real-time PCR data for OLIG1, BAHD1, and DMRTA1 normalized to the expression of CAMKK2. The error bars indicate the standard deviation of nine
different measurements per gene. The value for normal lung was established by taking the average mRNA expression of three different samples so as to
try to capture the potential variability in the normal expression of each of the genes. ***; significant at the 97.5% confidence level; N, normal lung; A,
adenocarcinoma; S, SCC.
(B) OLIG1, BAHD1, and DMRTA1 mRNA expression in A549 and H1299 cell lines treated with 1 lM 5-aza-dC for 72 h. The error bars indicate the standard
deviation of nine individual measurements.
(C) OLIG1 immunohistochemistry on untreated and 1 lM 5-aza-dC treated H1299 cells. Treatment times are indicated underneath each panel.
Photographs were taken at 4003 magnification.
(D) OLIG1 DNA level for adenocarcinomas and SCCs. Each bar represents one sample. The error bars indicate the standard deviation of three
independent measurements. Samples for which the level of OLIG1 DNA was significantly lower than that of its matching tumor-free lung DNA (p ,
0.050, one-tail Student’s t-test) are indicated with a star.
doi:10.1371/journal.pmed.0040108.g002
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OLIG1 in Human Lung Cancerexpression). Positive staining was detected in nuclei, indicat-
ing the correct localization of the target protein (Figure 5A–
5H). Our analysis determined that 78% (n ¼ 46) of
adenocarcinomas and 58% (n ¼ 42) of SCC were either
negative or expressed OLIG1 protein at low levels (Table S5).
In light of the high number of OLIG1 negative and low
expressing cases in both lung tumor subtypes, we hypothe-
sized that OLIG1 protein expression may inﬂuence survival in
NSCLC patients.
To test this hypothesis, univariate and multivariate analyses
were performed. All clinical and geographical variables
available for the dataset (gender, age, tumor subtype, and T
and N stages) were included in the models in order to account
for potentially confounding factors independent of OLIG1
index, which may affect survival. The results of these analyses
yielded a hazard ratio of 0.86 for OLIG1 index (95% CI 0.76–
0.98, p ¼ 0.023), indicating an association between reduced
OLIG1 protein expression and reduced overall survival. In
our analysis the OLIG1 index variable was composed of nine
discrete values (1–9), where 1 represents lack of protein
expression and 9 represents normal protein levels, as
described in the Methods section. Therefore, our results
Figure 3. OLIG1 Luciferase Promoter Assay and Bisulfite DNA Sequencing
(A) OLIG1 gene diagram and luciferase activity determined for four deletion constructs in A549 cells. The gene is represented by a gray box with an
arrow indicating the transcription start site. The location of the AscI site is indicated. The E2F3a promoter was used as a positive control for luciferase
activity. The error bars indicate the standard deviation of three independent triplicate transfections. The gene diagram and constructs are drawn upt o
scale.
(B) Bisulfite DNA sequencing of OLIG1 in two adenocarcinomas, two SCCs, and four tumor-free lung samples derived from the same patients. The gene
diagram on top indicates the relative location of the sequenced products in relation to the CpG sites within the CpG island (vertical lines), the
transcription start site (horizontal arrow), and the exon (gray box). A total of eight to ten clones were sequenced per sample. Each line represents an
individual clone and each circle represents a CpG dinucleotide. Solid circle, methylated cytosines; open circle, unmethylated cytosines; vertical arrow,
AscI site.
doi:10.1371/journal.pmed.0040108.g003
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OLIG1 in Human Lung Cancerindicate that for every unit increase in OLIG1 index, there is
a risk reduction of 14% in relation to the risk associated with
the lower index. For example, an OLIG1 index of 6 is
associated with a 14% reduction in the risk afforded by an
OLIG1 index of 5. By the same token, an OLIG1 index of 5 is
associated with a 14% decrease in the risk afforded by an
OLIG1 index of 4.
In order to validate our observations, OLIG1 immunohis-
tochemistry was performed on an independent sample set
(TMA2), comprising 74 adenocarcinomas (Adenos 104–182)
and 79 SCCs (SCCs 130–208). The tissue cores were scored as
previously described, and an OLIG1 index value was assigned
to each sample. After completion of the data collection,
univariate and multivariate analyses were performed on the
dataset. The analyses were carried out in the same manner as
for TMA1, including gender, age, tumor subtype, and T and N
stage variables in the models. For this second dataset, the
OLIG1 index hazard ratio was assessed at 0.83 (95% CI 0.74–
0.93, p ¼ 0.0012) lending further support to the observation
that reduced OLIG1 protein expression is associated with
reduced overall survival.
In an effort to improve the precision of the multivariate
model, TMA1 and TMA2 were combined and reanalyzed in
the same fashion as each individual dataset. The rationale for
this approach was to increase the sample number, thereby
increasing the statistical power and, potentially, the accuracy
of the analysis. The OLIG1 index hazard ratio for the
combined data was determined at 0.84 (95% CI 0.77–0.91
and p , 0.001). The complete Cox proportional hazard model
for TMA1 and TMA2 combined is shown in Table 2.
Finally, we calculated the OLIG1 index hazard ratio for
patients who were positive and negative for OLIG1 protein
expression. This hazard ratio was generated by dividing the
combined sample sets (n¼285) into two groups. Samples with
an OLIG1 index  3 were considered negative, while samples
with an index  4 were considered positive [25]. The hazard
ratio for this calculation was 0.54 (95% CI 0.38–0.761 and p ,
0.001), indicating a 54% lower risk for OLIG1-positive cases.
From this multivariate model, the probability of survival at
ﬁve years was calculated for both groups. For OLIG1-positive
cases, the probability of survival at ﬁve years was assessed at
0.62 (95% CI 0.55–0.70), while for OLIG1-negative cases the
probability of survival at ﬁve years was determined at 0.38
(95% CI 0.24–0.50). The difference between both survival
probabilities, 0.24, was statistically signiﬁcant (95% CI 0.11–
0.36), further strengthening our previous observations.
Overall, the comprehensive statistical analysis of our
datasets led us to conclude that reduced OLIG1 protein
expression is associated with reduced overall survival, and
this association is independent of clinical variables such as
tumor subtype, T and N stages, or geographical variables such
as gender and age. In particular we were able to show that
survival at 60 months, a common clinical parameter for
assessing lung cancer prognosis, is signiﬁcantly associated
with OLIG1 protein expression.
Discussion
In this study we have demonstrated that lung adenocarci-
nomas and SCCs can be distinguished by the DNA methyl-
ation status of 47 discrete loci. This is a remarkable
observation, since it not only lends further support to the
fact that aberrant CpG island methylation is nonrandom [10],
but it also indicates that different subtypes of neoplasias
arising from the same organ can potentially be distinguished
by their aberrant DNA methylation patterns.
One of the 47 aberrantly methylated loci was OLIG1, a basic
helix-loop-helix transcription factor required for oligoden-
drocyte differentiation but of unknown function in adult
lung [32]. Immunohistochemical analysis of a large set of
adenocarcinomas and SCCs uncovered missing or reduced
OLIG1 protein expression in 68% of the specimens tested,
suggesting that abrogation of OLIG1 might be of clinical
relevance in these subtypes of NSCLC. The impact of OLIG1
protein expression on patient survival was assessed by
univariate and multivariate analyses. Cox proportional
hazard models indicated that lack of OLIG1 protein was
strongly associated with poor survival in NSCLC patients.
Validation of these observations in an independent dataset
mirrored the results ﬁrst generated, further strengthening
this association. Altogether, our results suggest that OLIG1
protein expression may provide an additional clinically useful
parameter to determine the utility of supplementary therapy
for patients suffering from lung NSCLC, especially since
Figure 4. OLIG1 mRNA Expression in Primary Tumor Samples in Relation
to OLIG1 DNA Methylation Levels and Deletions at the OLIG1 Locus
Each circle represents a single sample. The presence of DNA methylation
and/or deletions is indicated at the bottom of each sample column.
mRNA expression levels are indicated in relation to normal lung, which
was arbitrarily set as 1.
doi:10.1371/journal.pmed.0040108.g004
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OLIG1 in Human Lung Cancersurvival at 60 months is signiﬁcantly correlated with OLIG1
protein expression. This ﬁnding is potentially of great
signiﬁcance, as the addition of postoperative adjuvant
chemotherapy in T2N0 NSCLC, for example, is currently a
matter of great debate [33,34].
The percentage of samples lacking OLIG1 protein was
higher than expected within the adenocarcinoma subgroup.
On the basis of the totality of the data collected in this study,
it is possible that a post-transcriptional mechanism acting
preferentially in the adenocarcinomas may account for either
lack of OLIG1 mRNA translation or rapid degradation of the
OLIG1 protein product. This scenario reconciles the initial
observations of lower DNA methylation and higher mRNA
expression in adenocarcinomas compared to SCCs with the
later ﬁnding of a higher proportion of OLIG1 negative
adenocarcinomas. Nevertheless, this phenomenon deserves
further investigation. The corroboration of a tumor subtype-
speciﬁc post-translational regulatory mechanism in lung
cancer would be an immense contribution toward further
understanding the etiology of this disease.
The importance of OLIG1 expression in adult lung may be
explained, in part, by extrapolation of known functions of
this gene in oligodendrocyte development [35,36]. It has been
shown that oligodendrocytes derived from OLIG1
 /  mice are
unable to differentiate [36], suggesting that at least one of the
functions of OLIG1 may pertain to initiation or maintenance
of cellular differentiation. At the same time, sonic hedgehog
(SHH), a secreted ligand of the hedgehog-signaling pathway
known to be overexpressed in lung cancer [37], has been
shown to be necessary and sufﬁcient to activate OLIG genes in
oligodendrocytes [38]. Thus, abrogation of OLIG1 protein
expression may play a role in inhibiting cellular differ-
Figure 5. OLIG1 Immunohistochemistry on a Lung Tissue Array
OLIG1 immunohistochemistry on (A and E) tumor-free lung, (B) an OLIG1 negative adenocarcinoma, and (F) an OLIG1 negative SCC; (C) a low OLIG1
expressing adenocarcinoma and (G) a low OLIG1 expressing SCC are shown; (D) a high OLIG1 expressing adenocarcinoma and (H) a high OLIG1
expressing SCC are shown. All images were acquired at 4003 magnification.
doi:10.1371/journal.pmed.0040108.g005
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OLIG1 in Human Lung Cancerentiation, but it could also contribute to the tumor
phenotype in other ways through some of its downstream
targets. MAG, a single-pass type I transmembrane protein
involved in brain cellular adhesion [39,40] is highly expressed
in adult lung [41], and it is also a known target of OLIG1 [39].
In light of these genetic interactions, a growth advantage
could be conferred to tumor cells that overexpress SHH
through interaction with currently unknown growth promot-
ing targets, while at the same time abrogating OLIG1
expression concomitant to MAG down-regulation. This
scenario would explain the high frequency of deletions and
DNA methylation observed at the OLIG1 locus. This
hypothesis is reinforced by our observation that N0 NSCLC
cases are more likely to be OLIG1 positive than N1 cases.
Therefore, this phenotypic difference could stem, in part,
from lack or reduced MAG expression in OLIG1 negative
tumors, which could facilitate detachment of tumor cells
from the primary tumor mass.
Taking into consideration the relationship between DNA
methylation and gene expression, our study demonstrates
that genome-wide DNA methylation patterns can be as useful
in tumor subtype distinction as gene expression proﬁling, an
approach that has been successfully utilized in the past to
distinguish not only lung tumor subtypes but also phenotypic
differences associated with survival within a lung tumor
subclass [42–44]. In light of our results, the establishment of
differential DNA methylation patterns could reﬂect an
intrinsic difference in the cellular origin [45] of each of the
tumor subtypes, or by distinct oncogenic pathways activated
predominantly in one subtype over the other. It has been well
documented that gains in 3q22–q26 where the alpha catalytic
subunit of phosphatidylinositol 3-kinase is located, occurs
almost exclusively in SCCs [46]. Overexpression of this gene
could be correlated with increased activity of its downstream
effector, protein kinase B, in this lung tumor subtype [46].
Given the evidence that DNA methylation may be the result
of a priori down-regulation of gene expression [47,48], the
establishment of differential DNA methylation patterns
between lung tumor subtypes may be the result of distinct
oncogenic activities affecting primarily one type of neoplasia
and not the other. Additional studies will be needed to fully
elucidate the mechanisms governing the establishment of
tumor subtype speciﬁc DNA methylation patterns.
Supporting Information
Alternative Language Abstract S1. Translation of the abstract into
Spanish by Romulo Martin Brena.
Found at doi:10.1371/journal.pmed.0040108.sd001 (21 KB DOC).
Figure S1. Olig1 Bisulﬁte DNA Sequencing in A549 and H1299 Cell
Lines
Found at doi:10.1371/journal.pmed.0040108.sg001 (459 KB TIF).
Table S1. Adenocarcinoma and SCC Samples Analyzed by RLGS to
Generate Clusters
All clusters are shown in Figure 1.
(A) Adenocarcinoma samples; samples A1 to A11 were used to
generate cluster 1B. Samples A12 to A19 were used to generate
cluster 1C. All samples are present in cluster 1D.
(B) Summary of the clinical and demographic characteristics for the
samples listed in part A; the age range is indicated in parenthesis.
(C) SCC samples; samples S1 to S14 were used to generate cluster 1B.
Samples S15 to S21 were used to generate cluster 1C. All samples are
present in cluster 1D.
(D) Summary of the clinical and demographic characteristics for the
samples listed in part C. The age range is indicated in parenthesis.
Found at doi:10.1371/journal.pmed.0040108.st001 (107 KB DOC).
Table S2. Clinical Characteristics for Tumor Samples Present in
TMA1 That Met All the Quality Control Criteria to Be Included in the
Analysis for OLIG1 Protein Expression
(A) Adenocarcinoma samples; the age range for the sample set is
indicated in brackets underneath the mean age value.
(B) SCC samples; the age range for the sample set is indicated in
brackets underneath the mean age value.
Found at doi:10.1371/journal.pmed.0040108.st002 (62 KB DOC).
Table S3. Clinical Characteristics for Tumor Samples Present in
TMA2 That Met All the Quality Control Criteria to Be Included in the
Analysis for OLIG1 Protein Expression
(A) Adenocarcinoma samples; the age range for the sample set is
indicated in brackets underneath the mean age value.
(B) SCC samples; the age range for the sample set is indicated in
brackets underneath the mean age value.
Found at doi:10.1371/journal.pmed.0040108.st003 (38 KB DOC).
Table S4. Average OLIG1 Index for Each of the Samples Used for
Immunohistochemistry in TMA1
Samples are classiﬁed into three categories: positive (index . 6),
negative (index , 4), and low level (index 4–5).
Found at doi:10.1371/journal.pmed.0040108.st004 (39 KB DOC).
Table S5. Primer Sequences and Conditions for All PCR Reactions
Performed in This Study
(A) Primer sequences and PCR conditions used to evaluate mRNA
expression in the genes listed on the left. The OLIG1 and CAMKK2
primers were also used to assess for OLIG1 deletions in primary
tumors.
(B) Primer sequences with their corresponding annealing temper-
atures used to amplify the BAHD1 and DMRTA1 for Bio-COBRA.
(C) Primer sequences with their corresponding annealing temper-
atures used to amplify the OLIG1 constructs used in the luciferase
assays.
(D) Primer sequences with their corresponding annealing temper-
atures used to amplify the OLIG1 regions selected for bisulﬁte DNA
sequencing.
Found at doi:10.1371/journal.pmed.0040108.st005 (146 KB DOC).
Accession Numbers
Accession numbers for all genes analyzed or mentioned in this study
can be found at UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼unigene).
Table 2. Multivariate Analysis of TMAs 1 and 2 Combined (n ¼
285)
Prognostic Factor Group Hazard Ratio 95% CI p-Value
OLIG1 Index 0.84 0.77–0.91 2.4 3 10
 5
Gender Female 1.00
Male 1.46 1.04–2.06 0.0310
Age ,67 1.00
 67 1.54 1.08–2.19 0.0160
Tumor subtype AdenoCa 1.00
SCC 1.05 0.75–1.48 0.7600
T stage 1 1.00
T stage 2 1.21 0.84–1.74 0.3000
T stage 3 2.64 1.45–4.80 0.0015
N stage 0 1.00
N stage 1 1.54 1.03–2.29 0.0340
N stage 2 1.99 0.70–5.64 0.2000
TMA 1 1.00
TMA 2 1.30 0.92–1.84 0.1400
doi:10.1371/journal.pmed.0040108.t002
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Editors’ Summary
Background. Lung cancer is the commonest cause of cancer-related
death worldwide. Most cases are of a type called non-small cell lung
cancer (NSCLC). Like other cancers, treatment of NCSLC depends on the
‘‘TNM stage’’ at which the cancer is detected. Staging takes into account
the size and local spread of the tumor (its T classification), whether
nearby lymph nodes contain tumor cells (its N classification), and
whether tumor cells have spread (metastasized) throughout the body (its
M classification). Stage I tumors are confined to the lung and are
removed surgically. Stage II tumors have spread to nearby lymph nodes
and are treated with a combination of surgery and chemotherapy. Stage
III tumors have spread throughout the chest, and stage IV tumors have
metastasized around the body; patients with both of these stages are
treated with chemotherapy alone. About 70% of patients with stage I or
II lung cancer, but only 2% of patients with stage IV lung cancer, survive
for five years after diagnosis.
Why Was This Study Done? TNM staging is the best way to predict the
likely outcome (prognosis) for patients with NSCLC, but survival times for
patients with stage I and II tumors vary widely. Another prognostic
marker—maybe a ‘‘molecular signature’’—that could distinguish
patients who are likely to respond to treatment from those whose
cancer will inevitably progress would be very useful. Unlike normal cells,
cancer cells divide uncontrollably and can move around the body. These
behavioral changes are caused by alterations in the pattern of proteins
expressed by the cells. But what causes these alterations? The answer in
some cases is ‘‘epigenetic changes’’ or chemical modifications of genes.
In cancer cells, methyl groups are aberrantly added to GC-rich gene
regions. These so-called ‘‘CpG islands’’ lie near gene promoters
(sequences that control the transcription of DNA into mRNA, the
template for protein production), and their methylation stops the
promoters working and silences the gene. In this study, the researchers
have investigated whether aberrant methylation patterns vary between
NSCLC subtypes and whether specific aberrant methylations are
associated with survival and can, therefore, be used prognostically.
What Did the Researchers Do and Find? The researchers used
‘‘restriction landmark genomic scanning’’ (RLGS) to catalog global
aberrant DNA methylation patterns in human lung tumor samples. In
RLGS, DNA is cut into fragments with a restriction enzyme (a protein that
cuts at specific DNA sequences), end-labeled, and separated using two-
dimensional gel electrophoresis to give a pattern of spots. Because
methylation stops some restriction enzymes cutting their target
sequence, normal lung tissue and lung tumor samples yield different
patterns of spots. The researchers used these patterns to identify 47 DNA
methylation targets (many in CpG islands) that together distinguished
between adenocarcinomas and squamous cell carcinomas, two major
types of NSCLCs. Next, they measured mRNA production from the genes
with the greatest difference in methylation between adenocarcinomas
and squamous cell carcinomas. OLIG1 (the gene that encodes a protein
involved in nerve cell development) had one of the highest differences in
mRNA production between these tumor types. Furthermore, three-
quarters of NSCLCs had reduced or no expression of OLIG1 protein and,
when the researchers analyzed the association between OLIG1 protein
expression and overall survival in patients with NSCLC, reduced OLIG1
protein expression was associated with reduced survival.
What Do These Findings Mean? These findings indicate that different
types of NSCLC can be distinguished by examining their aberrant
methylation patterns. This suggests that the establishment of different
DNA methylation patterns might be related to the cell type from which
the tumors developed. Alternatively, the different aberrant methylation
patterns might reflect the different routes that these cells take to
becoming tumor cells. This research identifies a potential new prognostic
marker for NSCLC by showing that OLIG1 protein expression correlates
with overall survival in patients with NSCLC. This correlation needs to be
tested in a clinical setting to see if adding OLIG1 expression to the
current prognostic parameters can lead to better treatment choices for
early-stage lung cancer patients and ultimately improve these patients’
overall survival.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040108.
  Patient and professional information on lung cancer, including staging
(in English and Spanish), is available from the US National Cancer
Institute
  The MedlinePlus encyclopedia has pages on non-small cell lung cancer
(in English and Spanish)
  Cancerbackup provides patient information on lung cancer
  CancerQuest, provided by Emory University, has information about
how cancer develops (in English, Spanish, Chinese and Russian)
  Wikipedia pages on epigenetics (note that Wikipedia is a free online
encyclopedia that anyone can edit)
  The Epigenome Network of Excellence gives background information
and the latest news about epigenetics (in several European languages)
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